Financial News

Exicure to Present at Upcoming TIDES USA Oligonucleotide & Peptide Therapeutics Conference

Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced a poster presentation at TIDES USA 2022, May 9-12, 2022.

Poster presentation: “Development of Spherical Nucleic Acids Targeting SCN9A For the Treatment of Neuropathic Pain” – Poster Board Assignment Number: 54

Exicure will have the poster for viewing both in-person and virtually during the conference. Virtual posters will go live at the start of the conference and will be available to conference attendees for 2 weeks.

Exicure will add the poster to its website after the conference.

About Exicure

Exicure, Inc. is an early-stage biotechnology company developing nucleic acid therapies targeting ribonucleic acid against validated targets to neurological disorders and hair loss. The team includes a diverse scientific group with expertise in nucleic acid chemistry, drug development and neuroscience. Headquartered in Chicago, Illinois, the Company conducts its discovery and development efforts in-house with a dedicated 30,000 square foot facility, including rapid and automated high throughput nucleic acid synthesis and screening.

For further information, see www.exicuretx.com.

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback